Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

Article Immunology

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients

Lu Lu et al.

Summary: Immune sera from BNT162b2 and Coronavac recipients showed reduced neutralizing antibody titers against the omicron variant. The presence of the spike R346K mutation did not affect the neutralization susceptibility.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

Akatsuki Saito et al.

Summary: During the COVID-19 pandemic, the B.1.617.2/Delta variant has been found to be highly fusogenic and more pathogenic in infected hamsters compared to prototypic SARS-CoV-2. The P681R mutation in the spike protein of this variant enhances viral fusogenicity and pathogenicity.

NATURE (2022)

添加到收藏夹

Article Immunology

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron

Youchun Wang et al.

Summary: The Omicron variant shows greater potential for immune escape compared to other variants, suggesting a significant impact on immunity from previous infections and vaccines.

EMERGING MICROBES & INFECTIONS (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases

Jie Zhou et al.

Summary: The development of broad-spectrum antivirals against human coronaviruses is crucial for combating the COVID-19 pandemic and future outbreaks. A new lipopeptide drug, EKL1C, has potent inhibitory activity against SARS-CoV-2 and its variants, as well as other coronaviruses. It exhibits better stability and metabolic stability compared to previous drugs, making it a potential candidate for COVID-19 and other coronavirus diseases.

ACTA PHARMACEUTICA SINICA B (2022)

添加到收藏夹

News Item Multidisciplinary Sciences

HEAVILY MUTATED OMICRON VARIANT PUTS SCIENTISTS ON ALERT

Ewen Callaway

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant

Jun Zhang et al.

Summary: The Delta variant of SARS-CoV-2 is more efficient at fusing membranes at low levels of cellular receptor ACE2, possibly contributing to its heightened transmissibility. Each variant shows different rearrangement of the antigenic surface of the S protein, but only the changes in the RBD make it a better target for therapeutic antibodies.

SCIENCE (2021)

添加到收藏夹

Article Medicine, Research & Experimental

SARS-CoV-2 Omicron variant: Characteristics and prevention

Xuemei He et al.

Summary: The new SARS-CoV-2 variant B.1.1.529 named Omicron, reported in South Africa, has raised global concerns after being designated as a variant of concern by the WHO. With a high number of mutations, including 15 in the spike receptor-binding domain, the Omicron variant shares similarities with previous VOCs, sparking worries about its transmissibility and immune evasion.

MEDCOMM (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation

Shuai Xia et al.

Summary: The COVID-19 pandemic and its variants pose a global threat to public health and economy. EK1 and EK1C4 demonstrate potent antiviral activity against SARS-CoV-2 infection, with potential for further clinical development.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Cell Biology

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Shuai Xia et al.

CELL RESEARCH (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Shuai Xia et al.

SCIENCE ADVANCES (2019)

添加到收藏夹

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

相关参考文献

导出引文

分享论文